# iRadimed Corporation

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/iRadimed Corporation).

## Overview

IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service. The company serves hospitals and acute care facilities that need equipment that can operate safely in the magnetic environment of MRI suites.

## Products & services

• MRidium 3870 MRI-compatible IV infusion pump system
• MRidium 3860+ MRI-compatible IV infusion pump system
• 3880 MRI-compatible patient vital signs monitoring system
• 3600 FMD1 with RALU ferromagnetic detection system
• Disposable IV tubing sets and monitor disposables
• Extended maintenance agreements and service support

- **MRI-compatible infusion pump systems** (45%) — Scanner-room infusion pumps and associated tubing sets used to deliver medication during MRI procedures.
- **MRI-compatible patient monitoring systems** (27%) — Vital signs monitoring systems designed to function safely in MRI environments.
- **Disposables** (21%) — Single-use tubing and related consumables sold with installed devices and recurring usage.
- **Service and maintenance** (7%) — Extended maintenance agreements, service work, and other support tied to installed equipment.

- MRidium 3870 MRI-compatible IV infusion pump system
- MRidium 3860+ MRI-compatible IV infusion pump system
- 3880 MRI-compatible patient vital signs monitoring system
- 3600 FMD1 with RALU ferromagnetic detection system
- Disposable IV tubing sets and monitor disposables
- Extended maintenance agreements and service support

## Customers

IRADIMED sells primarily to hospitals and acute care facilities with MRI equipment on site, where clinical staff need infusion and monitoring tools that are safe in the scanner room. In the U.S., the company sells largely to end users, while internationally it relies more on distributors, which affects pricing, support, and customer access.

- **Hospitals with MRI suites** (primary) — Buy infusion pumps, monitors, and disposables for safe use during MRI procedures and to improve workflow.
- **Acute care facilities** (primary) — Purchase MRI-compatible devices for critical-care imaging environments where patient monitoring is essential.
- **International distributors** (secondary) — Buy products for resale outside the U.S., extending market reach where direct selling is less practical.
- **Installed-base customers** (secondary) — Purchase disposables, service, and maintenance tied to existing IRADIMED equipment.

- Hospitals buying MRI-safe infusion pumps for scanner-room use
- Acute care facilities needing MRI-compatible patient monitoring
- Clinical departments that decide based on workflow and safety needs
- U.S. end users purchasing directly on open credit terms
- International distributors reselling into local hospital markets
- Installed-base customers buying disposables and maintenance

## Geography

The business is heavily U.S.-centric, with 84% of 2025 revenue generated in the United States and 16% from international markets. International sales are supported through distributors, while the company manufactures and stores products at a single facility in Florida, creating both operational focus and concentration risk.

- **United States** (84%)
- **International** (16%)

- United States generated 84% of 2025 revenue
- International markets generated 16% of 2025 revenue
- International sales are mainly routed through distributors
- Manufacturing and storage are concentrated in Florida
- Single-site operations increase supply and continuity risk

## Strategy

IRADIMED is focused on growing its installed base in MRI-compatible devices while expanding recurring revenue from disposables, service, and maintenance. The company is also investing in capacity and product development, including a new facility and in-house manufacturing capability for certain components, to support growth and reduce supply dependence.

- **Grow installed base and recurring revenue** (medium-term) — Recurring disposables and service improve revenue visibility and leverage the installed base.
- **Expand manufacturing capacity** (short-term) — The new facility is intended to accommodate growth and support operations at higher scale.
- **Reduce supplier concentration** (medium-term) — Single-sourced components create continuity risk, so internalizing key parts can improve resilience.
- **Drive product awareness and market share in MRI monitoring** (medium-term) — The 3880 monitor competes against established brands, so adoption depends on workflow and differentiation.

- Expand adoption of MRI-compatible infusion and monitoring systems
- Grow recurring revenue from disposables and maintenance agreements
- Invest in a new facility to support anticipated growth
- Reduce supply-chain dependence through in-house component manufacturing
- Support product development and regulatory approvals
- Use direct sales and service specialists to deepen customer relationships

## Risks

IRADIMED faces concentration risk from a limited product set, a single manufacturing site, and reliance on key suppliers for specialized components. It also operates in a regulated, competitive medical-device market where FDA approvals, trade restrictions, distributor execution, and long sales cycles can delay growth or pressure margins.

- **Product concentration** [high] — A large share of revenue comes from a small number of MRI-compatible devices, so demand shifts can materially affect results.
- **Single-site manufacturing and storage** [high] — Manufacturing and inventory are concentrated in one Florida facility, increasing disruption risk from operational events.
- **Supply-chain dependence** [high] — Critical raw materials and parts are sourced from single suppliers, including Chinese and Taiwanese manufacturers.
- **Regulatory approval risk** [medium] — Medical-device commercialization depends on FDA clearances and ongoing compliance, which can delay launches or require redesigns.
- **Competitive pressure** [medium] — Larger rivals have broader product lines, deeper resources, and established customer relationships.
- **International distributor dependence** [medium] — Non-U.S. sales rely on third parties, which can weaken pricing control and execution quality.

- Limited product portfolio increases dependence on a few device lines
- Single Florida facility creates operational and continuity concentration risk
- Single-source components and trade restrictions can disrupt supply
- FDA and other regulatory approvals can delay new product launches
- Competition from larger medical-device companies can limit share gains
- International sales depend on distributors and foreign compliance

## Accounting

Key accounting judgments include revenue recognition across devices, disposables, maintenance agreements, and service, as well as estimates for returns, doubtful accounts, inventory valuation, and long-lived asset impairment. Results are also affected by seasonality in bookings, capitalized facility spending, stock-based compensation, lease accounting, and tax estimates, all of which can move reported margins and earnings.

- **Revenue recognition by product type** — Can shift revenue between periods and affect gross margin trends
- **Allowance for doubtful accounts** — Affects operating income and receivables valuation
- **Inventory valuation** — Can materially affect cost of revenue and gross profit
- **Long-lived asset and facility depreciation** — Affects operating expense run-rate and asset carrying values
- **Income tax estimates and credits** — Can move effective tax rate and net income
- **Seasonality** — Can create uneven revenue and order trends

- Revenue mix includes devices, disposables, maintenance amortization, and service
- Maintenance agreement amortization affects timing of recognized revenue
- Allowance for doubtful accounts matters because U.S. sales are on credit
- Inventory valuation is important due to specialized components and single sourcing
- New facility spending affects depreciation and capitalized asset balances
- Seasonal third-quarter booking weakness can distort quarterly comparisons

---

*Last updated: 2026-04-28T20:16:43.258128+00:00*